FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308407007> ?p ?o ?g. }

• W4308407007 abstract "<h3>Background</h3> Single agent anti-PD1 therapy has shown limited clinical benefit in liposarcoma, but combination with anti-CTLA-4 demonstrated a higher response rate.^1-3 In the MDACC study NCT02815995, combining anti-CTLA4 and anti-PDL1 across multiple soft-tissue sarcomas increased CD73, PD-1, and OX40 expression in T cells early on treatment. The adenosine pathway, which includes CD73 and the A2A receptor, induces immunosuppression^4,5 and protects from antitumoral responses.^{6, 7} This pathway is related to immune therapy resistance^8-11, metastasis, and poor prognosis.^12-15 Conversely, CD73+ T cells have long-lived memory and higher proliferation and survival, suggesting a dual role of the pathway.^16-18 We hypothesized that adenosine would negatively correlate with TIL expansion and function. <h3>Methods</h3> Surgically resected liposarcoma samples (n=41), are divided for fresh tissue phenotyping by flow cytometry, TIL expansion, and quantification of tissue adenosine, cytokines, and adipokines. The phenotypic analysis included: CD73, A2aR, PD-1, Tim3, CTLA-4, LAG3, OX40, ICOS and 41BB markers. TIL 3.0 expansion protocol¹⁹ was performed, and expanded TIL were assessed for cytotoxicity by IFN-g production and metabolic state (ROS, mitochondrial activity) by flow cytometry. <h3>Results</h3> We found high heterogeneity in the frequency of CD45+ cells (0-88.3%), CD4+ and CD8+ TIL infiltrate, and expression of PD-1 (0.66-59.60% and 0.99-76.6% respectively), CD73 (CD4+ 0- 40.97%, CD8+ 0-34.04%), and A2AR (mean CD4+ 0-0.6%, CD8+ 0-17.96%), with no co-expression of CD73 and A2AR. Interestingly adenosine concentration was highly variable (0-84.05 nmol/g tissue) but did not correlate with TIL phenotype or tissue cytokines. Tumors were rich in growth factors and chemokines but lacked a pro-inflammatory profile. The success of TIL expansion was 50% (n=24 cases) in samples with a count of 300 CD3+ events in the fresh tissue by flow analysis. The frequency of CD8+CD73+ TIL was significantly higher in cases with successful TIL expansion (p=0.041). The expanded TIL phenotype showed CD73 expression (range: CD4+ 0.67-29 % and CD8+ 0.85-13.9%) and upregulation of A2AR (range: 0.2-15.40% and 1.44-87.6%). IFN-g production was related to intrinsic metabolic profiles by mitochondrial mass and ROS production (n=8). <h3>Conclusions</h3> A heterogeneous adenosine landscape was found in liposarcoma. A2AR but not CD73 correlated with mitochondrial dysfunction and reduced cytotoxicity. Conversely CD73+ TIL were more likely to expand. Our results indicate a dichotomy in two key members in the adenosine pathway in liposarcoma and suggest that CD73 might play a positive role in TIL function. <h3>Acknowledgements</h3> Patients and their families. CCSG Metabolomics Core (Grant P30CA016672) Philanthropy support provided by a generous donation by the William Oates family <h3>References</h3> Klaver Y, <i>et al</i>. Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes. <i>J Immunother Cancer</i> 2020;<b>8</b>(2). Livingston JA, <i>et al</i>. Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. <i>Sci Rep</i>, 2017;<b>7</b>(1):11836. D’Angelo SP, <i>et al</i>. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. <i>Lancet Oncol</i> 2018;<b>19</b>(3):416–426. Jin D, <i>et al</i>. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. <i>Cancer Res</i> 2010;<b>70</b>(6):2245–55. Allard B, <i>et al</i>. The adenosine pathway in immuno-oncology. <i>Nat Rev Clin Oncol</i> 2020;<b>17</b>(10):611–629. Mastelic-Gavillet, B., <i>et al</i>., Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8(+) T cells. <i>J Immunother Cancer</i> 2019;<b>7</b>(1):257. Ohta A, <i>et al</i>. A2A adenosine receptor protects tumors from antitumor T cells. <i>Proc Natl Acad Sci U S A</i> 2006;<b>103</b>(35):13132–7. Zhou L, <i>et al</i>. The distinct role of CD73 in the progression of pancreatic cancer. <i>J Mol Med (Berl)</i> 2019;<b>97</b>(6):803–815. Wu R, <i>et al</i>. Effects of CD73 on human colorectal cancer cell growth in vivo and in vitro. <i>Oncol Rep</i> 2016;<b>35</b>(3):1750–6. Chen S <i>et al</i>. CD73 expression on effector T cells sustained by TGF-beta facilitates tumor resistance to anti-4-1BB/CD137 therapy. <i>Nat Commun</i> 2019;<b>10</b>(1):150. Cekic C <i>et al</i>. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. <i>Cancer Res</i> 2014;<b>74</b>(24):7250–9. Turcotte M <i>et al</i>. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. <i>Cancer Res</i> 2015;<b>75</b>(21):4494–503. Panigrahi S, <i>et al</i>., CD8(+) CD73(+) T cells in the tumor microenvironment of head and neck cancer patients are linked to diminished T cell infiltration and activation in tumor tissue. <i>Eur J Immunol</i> 2020;<b>50</b>(12):2055–2066. Gao Z.W, <i>et al</i>. CD73 promotes proliferation and migration of human cervical cancer cells independent of its enzyme activity. <i>BMC Cancer</i> 2017;<b>17</b>(1):135. Koszalka P, <i>et al</i>. Targeted disruption of cd73/ecto-5’-nucleotidase alters thromboregulation and augments vascular inflammatory response. <i>Circ Res</i> 2004;<b>95</b>(8):814–21. Capone M, <i>et al</i>. Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients.<i> J Transl Med</i> 2020;<b>18</b>(1):121. Rosemblatt MV, <i>et al</i>. Ecto-5’-Nucleotidase (CD73) Regulates the Survival of CD8+ T Cells. <i>Front Cell Dev Biol</i> 2021;<b>9</b>:647058. Fang F, <i>et al</i>. The cell-surface 5’-nucleotidase CD73 defines a functional T memory cell subset that declines with age. <i>Cell Rep</i> 2021;<b>37</b>(6):109981. Tavera RJ. <i>et al</i>. Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.<i> J Immunother</i> 2018;<b>41</b>(9):399–405. <h3>Ethics Approval</h3> This study was written and conducted in accordance with the principles from the Declaration of Helsinki. Written informed consent was provided by all study participants or their legal representatives. The study was approved by the University of Texas MD Anderson Cancer Center‘s Institutional Review Board." @default.
• W4308407007 created "2022-11-11" @default.
• W4308407007 creator A5011384237 @default.
• W4308407007 creator A5019756853 @default.
• W4308407007 creator A5022670258 @default.
• W4308407007 creator A5023832478 @default.
• W4308407007 creator A5050132330 @default.
• W4308407007 creator A5052927134 @default.
• W4308407007 creator A5054595254 @default.
• W4308407007 creator A5065709859 @default.
• W4308407007 creator A5076321493 @default.
• W4308407007 creator A5087234749 @default.
• W4308407007 creator A5087927133 @default.
• W4308407007 creator A5089849331 @default.
• W4308407007 date "2022-11-01" @default.
• W4308407007 modified "2023-09-23" @default.
• W4308407007 title "1042 The dual function of the adenosine pathway in the liposarcoma tumor microenvironment" @default.
• W4308407007 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1042" @default.
• W4308407007 hasPublicationYear "2022" @default.
• W4308407007 type Work @default.
• W4308407007 citedByCount "0" @default.
• W4308407007 crossrefType "proceedings-article" @default.
• W4308407007 hasAuthorship W4308407007A5011384237 @default.
• W4308407007 hasAuthorship W4308407007A5019756853 @default.
• W4308407007 hasAuthorship W4308407007A5022670258 @default.
• W4308407007 hasAuthorship W4308407007A5023832478 @default.
• W4308407007 hasAuthorship W4308407007A5050132330 @default.
• W4308407007 hasAuthorship W4308407007A5052927134 @default.
• W4308407007 hasAuthorship W4308407007A5054595254 @default.
• W4308407007 hasAuthorship W4308407007A5065709859 @default.
• W4308407007 hasAuthorship W4308407007A5076321493 @default.
• W4308407007 hasAuthorship W4308407007A5087234749 @default.
• W4308407007 hasAuthorship W4308407007A5087927133 @default.
• W4308407007 hasAuthorship W4308407007A5089849331 @default.
• W4308407007 hasBestOaLocation W43084070071 @default.
• W4308407007 hasConcept C134018914 @default.
• W4308407007 hasConcept C142724271 @default.
• W4308407007 hasConcept C153911025 @default.
• W4308407007 hasConcept C167672396 @default.
• W4308407007 hasConcept C185592680 @default.
• W4308407007 hasConcept C203014093 @default.
• W4308407007 hasConcept C2776107976 @default.
• W4308407007 hasConcept C2776991684 @default.
• W4308407007 hasConcept C2777701055 @default.
• W4308407007 hasConcept C2778256501 @default.
• W4308407007 hasConcept C2779568860 @default.
• W4308407007 hasConcept C502942594 @default.
• W4308407007 hasConcept C553184892 @default.
• W4308407007 hasConcept C71924100 @default.
• W4308407007 hasConcept C86803240 @default.
• W4308407007 hasConcept C8891405 @default.
• W4308407007 hasConceptScore W4308407007C134018914 @default.
• W4308407007 hasConceptScore W4308407007C142724271 @default.
• W4308407007 hasConceptScore W4308407007C153911025 @default.
• W4308407007 hasConceptScore W4308407007C167672396 @default.
• W4308407007 hasConceptScore W4308407007C185592680 @default.
• W4308407007 hasConceptScore W4308407007C203014093 @default.
• W4308407007 hasConceptScore W4308407007C2776107976 @default.
• W4308407007 hasConceptScore W4308407007C2776991684 @default.
• W4308407007 hasConceptScore W4308407007C2777701055 @default.
• W4308407007 hasConceptScore W4308407007C2778256501 @default.
• W4308407007 hasConceptScore W4308407007C2779568860 @default.
• W4308407007 hasConceptScore W4308407007C502942594 @default.
• W4308407007 hasConceptScore W4308407007C553184892 @default.
• W4308407007 hasConceptScore W4308407007C71924100 @default.
• W4308407007 hasConceptScore W4308407007C86803240 @default.
• W4308407007 hasConceptScore W4308407007C8891405 @default.
• W4308407007 hasLocation W43084070071 @default.
• W4308407007 hasOpenAccess W4308407007 @default.
• W4308407007 hasPrimaryLocation W43084070071 @default.
• W4308407007 hasRelatedWork W2904909612 @default.
• W4308407007 hasRelatedWork W3025154575 @default.
• W4308407007 hasRelatedWork W3028822667 @default.
• W4308407007 hasRelatedWork W3108853735 @default.
• W4308407007 hasRelatedWork W3125366473 @default.
• W4308407007 hasRelatedWork W4286629873 @default.
• W4308407007 hasRelatedWork W4291378227 @default.
• W4308407007 hasRelatedWork W4304979265 @default.
• W4308407007 hasRelatedWork W4312075079 @default.
• W4308407007 hasRelatedWork W4362003594 @default.
• W4308407007 isParatext "false" @default.
• W4308407007 isRetracted "false" @default.
• W4308407007 workType "article" @default.